A5076316380- Monoclonal and Polyclonal Antibodies Research
- CAR-T cell therapy research
- Nanofabrication and Lithography Techniques
- Cardiovascular Effects of Exercise
- Advanced Biosensing Techniques and Applications
- HER2/EGFR in Cancer Research
- Cardiac Imaging and Diagnostics
- Infective Endocarditis Diagnosis and Management
- Otolaryngology and Infectious Diseases
- Cardiovascular and exercise physiology
- Cardiac electrophysiology and arrhythmias
- Neuroblastoma Research and Treatments
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
- Streptococcal Infections and Treatments
- Healthcare Education and Workforce Issues
Western University of Health Sciences
2020-2022
University of California Davis Medical Center
2020
Northwestern University
2018
Midwestern University
2018
Anti-HER2/CD3, a T-cell-dependent bispecific antibody (TDB) construct, induces T-cell-mediated cell death in cancer cells expressing HER2 by cross-linking tumor with CD3 on cytotoxic T cells, thereby creating functional cytolytic synapse. TDB design is very challenging process that requires consideration of multiple parameters. Although therapeutic strategy commonly driven striving for the highest attainable antigen-binding affinity, little known about how affinity each arm can affect...
Aggregatibacter aphrophilus, formerly known as Haemophilus is one member of a group bacteria referred to HACEK (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) organisms. Infections from any the organisms typically lead very poor outcomes and can be difficult manage, especially when complicated by intracranial hemorrhage (ICH). also grow on blood cultures, A. aphrophilus rarely seen, if at all. Traditionally, most laboratories follow an extended incubation protocol 14 21...
<p>Supplemental Methods, followed by Supplemental Figures S1, S2, S3, S4 and S5. Supplementary Fig. S1 In vitro binding of TDBs to HER2 CD3 expressing cell lines. S2 expression in model lines tumors vivo. S3 HER2, CD3� MECA-32 staining vascular characterization positive negative tumors. T infiltration murine CT26 CT26-HER2 S5 Pharmacokinetic data from whole blood pellet fractions</p>
<p>Supplemental Methods, followed by Supplemental Figures S1, S2, S3, S4 and S5. Supplementary Fig. S1 In vitro binding of TDBs to HER2 CD3 expressing cell lines. S2 expression in model lines tumors vivo. S3 HER2, CD3� MECA-32 staining vascular characterization positive negative tumors. T infiltration murine CT26 CT26-HER2 S5 Pharmacokinetic data from whole blood pellet fractions</p>
<div>Abstract<p>Anti-HER2/CD3, a T-cell–dependent bispecific antibody (TDB) construct, induces T-cell–mediated cell death in cancer cells expressing HER2 by cross-linking tumor with CD3 on cytotoxic T cells, thereby creating functional cytolytic synapse. TDB design is very challenging process that requires consideration of multiple parameters. Although therapeutic strategy commonly driven striving for the highest attainable antigen-binding affinity, little known about how...
<div>Abstract<p>Anti-HER2/CD3, a T-cell–dependent bispecific antibody (TDB) construct, induces T-cell–mediated cell death in cancer cells expressing HER2 by cross-linking tumor with CD3 on cytotoxic T cells, thereby creating functional cytolytic synapse. TDB design is very challenging process that requires consideration of multiple parameters. Although therapeutic strategy commonly driven striving for the highest attainable antigen-binding affinity, little known about how...